AU2012312902B2 - Estrogen receptor ligands and methods of use thereof - Google Patents

Estrogen receptor ligands and methods of use thereof Download PDF

Info

Publication number
AU2012312902B2
AU2012312902B2 AU2012312902A AU2012312902A AU2012312902B2 AU 2012312902 B2 AU2012312902 B2 AU 2012312902B2 AU 2012312902 A AU2012312902 A AU 2012312902A AU 2012312902 A AU2012312902 A AU 2012312902A AU 2012312902 B2 AU2012312902 B2 AU 2012312902B2
Authority
AU
Australia
Prior art keywords
compound
another embodiment
prostate cancer
levels
crpc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012312902A
Other languages
English (en)
Other versions
AU2012312902A1 (en
Inventor
Christopher C. Coss
James Dalton
Mitchell S. Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
GTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/215,679 external-priority patent/US9427418B2/en
Application filed by GTx Inc filed Critical GTx Inc
Priority claimed from PCT/US2012/052141 external-priority patent/WO2013043304A1/en
Publication of AU2012312902A1 publication Critical patent/AU2012312902A1/en
Application granted granted Critical
Publication of AU2012312902B2 publication Critical patent/AU2012312902B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AU2012312902A 2011-08-23 2012-08-23 Estrogen receptor ligands and methods of use thereof Ceased AU2012312902B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/215,679 US9427418B2 (en) 2009-02-23 2011-08-23 Estrogen receptor ligands and methods of use thereof
US13/215,679 2011-08-23
PCT/US2012/052141 WO2013043304A1 (en) 2009-02-23 2012-08-23 Estrogen receptor ligands and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2012312902A1 AU2012312902A1 (en) 2013-05-23
AU2012312902B2 true AU2012312902B2 (en) 2016-03-17

Family

ID=48444651

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012312902A Ceased AU2012312902B2 (en) 2011-08-23 2012-08-23 Estrogen receptor ligands and methods of use thereof

Country Status (10)

Country Link
EP (1) EP2747562A4 (he)
JP (1) JP2014524479A (he)
KR (1) KR20140064906A (he)
CN (1) CN103957706A (he)
AU (1) AU2012312902B2 (he)
CA (1) CA2845890A1 (he)
IL (1) IL231070A0 (he)
IN (1) IN2014DN01959A (he)
MX (1) MX2014002105A (he)
RU (1) RU2014111060A (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3688008A1 (en) * 2017-09-27 2020-08-05 TargImmune Therapeutics AG Castration resistant prostate cancer
AU2020215116A1 (en) * 2019-02-01 2021-09-02 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Methods of treating castrate-resistant prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265296A1 (en) * 2005-11-28 2007-11-15 Dalton James T Nuclear receptor binding agents
US20100267773A1 (en) * 2005-11-28 2010-10-21 Dalton James T Estrogen receptor ligands and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135407A1 (en) * 2005-11-28 2007-06-14 Steiner Mitchell S Serm reduction of lipid profiles
WO2010096801A1 (en) * 2009-02-23 2010-08-26 Gtx, Inc. Estrogen receptor ligands and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265296A1 (en) * 2005-11-28 2007-11-15 Dalton James T Nuclear receptor binding agents
US20100267773A1 (en) * 2005-11-28 2010-10-21 Dalton James T Estrogen receptor ligands and methods of use thereof

Also Published As

Publication number Publication date
EP2747562A4 (en) 2015-05-06
EP2747562A1 (en) 2014-07-02
IL231070A0 (he) 2014-03-31
CN103957706A (zh) 2014-07-30
AU2012312902A1 (en) 2013-05-23
RU2014111060A (ru) 2015-09-27
IN2014DN01959A (he) 2015-05-15
CA2845890A1 (en) 2013-03-28
KR20140064906A (ko) 2014-05-28
MX2014002105A (es) 2014-09-25
JP2014524479A (ja) 2014-09-22

Similar Documents

Publication Publication Date Title
CA2753436C (en) Estrogen receptor ligands and methods of use thereof
US9051267B2 (en) Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) Estrogen receptor ligands and methods of use thereof
US20140187641A1 (en) Estrogen receptor ligands and methods of use thereof
US9815776B2 (en) Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2018201450A1 (en) A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10093613B2 (en) Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9409856B2 (en) Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) Nuclear receptor binding agents
US9624161B2 (en) Estrogen receptor ligands and methods of use thereof
US20140057985A1 (en) Estrogen receptor ligands and methods of use thereof
AU2012312902B2 (en) Estrogen receptor ligands and methods of use thereof
US20140057946A1 (en) Estrogen receptor ligands and methods of use thereof
WO2013043304A1 (en) Estrogen receptor ligands and methods of use thereof
AU2010215809B2 (en) Estrogen receptor ligands and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired